Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
The Medical Oncology Clinical Research team, based within the Mater Cancer Care Centre, currently has 22 actively recruiting trials.
Medicinal cannabis for advanced cancer patients – driving implications
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
A clinical trial to evaluate the efficacy and safety of MK-5475 for treating pulmonary hypertension associated with chronic obstructive pulmonary disease.
A placebo controlled clinical trial to evaluate direct administration of anti-epileptic medication to the brain in patients with treatment refractory focal epilepsy
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
This study is trialing a novel drug, called JNT-517, which works by increasing excretion of phenylalanine in the urine to reduce circulating levels in the blood.
Trial Status:
Active, not recruiting
|
Neuromodulation Using Scanning Ultrasound in Alzheimer’s Disease
This study is assessing the safety and effectiveness of a new anti-epileptic drug, called ganaxalone in patients admitted to the Intensive Care Unit with status epilepticus that has failed to respond to two other anti-epileptic medications.
Trial Status:
Active, not recruiting
|
A clinical trial to test the effectiveness and safety of CVL-865 for treatment of drug-resistant focal onset epilepsy